Advarra Announces Advarra GPS
Advarra, the provider of institutional review board (IRB), institutional biosafety committee (IBC), research quality and compliance consulting services, and standards-based research technology solutions, announces Advarra GPS-a completely managed service to guide, protect, and streamline research programs for health systems, hospitals, and academic medical centers. Advarra GPS helps institutions navigate the challenges of operating a local IRB office and chart a path to increased efficiency, greater compliance, and overall scalability.
“We continue to offer our institutional partners new services to guide and improve their research programs. Advarra GPS is truly an innovation that demonstrates our commitment to supporting research institutions as they navigate an increasingly complex and challenging landscape,” said Pat Donnelly, CEO of Advarra. “Our commitment to research compliance services for institutions is unwavering. From our recent acquisition of the industry’s leading CTMS, OnCore by Forte, to the launch of Advarra GPS and many innovations to come, the future of research powered by Advarra is exciting. ”
Advarra offers the institutional reach of any independent IRB, serving well over 3,200 research institutions, health systems, and academic medical centers.
“Navigating research regulations and maintaining a local IRB office is complex and costly. Research institutions often seek increased capacity,” said James Riddle, Vice President of Institutional Services at Advarra. “Advarra GPS charts a course to success by providing a roadmap to guide these organizations through compliance risks, protect from staffing challenges, and streamline approval times.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
